Xilio Therapeutics (XLO) director granted options for 5,000 shares at $7.99

Rhea-AI Filing Summary

Xilio Therapeutics director Aoife Brennan received a new stock option grant. The award covers 5,000 shares of common stock at an exercise price of $7.99 per share, expiring on June 10, 2036. It vests 100% on June 11, 2027 or at the next annual stockholder meeting, subject to continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brennan Aoife

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	5,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 5,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 5,000 shares Exercise price: $7.99 per share Post-transaction derivative holdings: 5,000 options +2 more

5 metrics

Option grant size 5,000 shares Stock Option (right to buy) granted June 11, 2026

Exercise price $7.99 per share Conversion or exercise price of stock option

Post-transaction derivative holdings 5,000 options Total derivative securities following transaction

Expiration date June 10, 2036 Option expiration date

Vesting date trigger June 11, 2027 or next annual meeting Earlier of these dates, subject to continued service

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 7.9900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"will vest as to 100% of the shares underlying the option"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders following the grant date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brennan Aoife

(Last) (First) (Middle)

828 WINTER STREET

SUITE 300

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xilio Therapeutics, Inc. [ XLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.99	06/11/2026		A		5,000		(1)	06/10/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

	/s/ Christopher Frankenfield, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Xilio Therapeutics (XLO) report for Aoife Brennan?

Xilio Therapeutics reported that director Aoife Brennan received a grant of stock options for 5,000 shares of common stock. The options are compensation-related and give her the right to buy shares at a fixed exercise price if they vest.

How many Xilio Therapeutics (XLO) shares are covered by Brennan's new option grant?

The new stock option grant to Aoife Brennan covers 5,000 shares of Xilio Therapeutics common stock. This entire amount remains outstanding after the transaction, as reflected in the post-transaction holdings figure of 5,000 derivative securities reported in the filing.

What is the exercise price and expiration date of Aoife Brennan’s Xilio (XLO) options?

Aoife Brennan’s stock options have an exercise price of $7.99 per share and expire on June 10, 2036. This means she can buy up to 5,000 Xilio common shares at $7.99 any time before that expiration date, once the options vest.

When do Aoife Brennan’s Xilio Therapeutics (XLO) options vest?

The options will vest 100% on the earlier of June 11, 2027 or Xilio’s next annual meeting of stockholders after the June 11, 2026 grant date. Vesting is conditioned on Brennan continuing to serve the company through the applicable vesting date.

Is Aoife Brennan’s Xilio (XLO) Form 4 transaction an open-market stock purchase?

No. The Form 4 shows a compensation-related grant of stock options, coded as a grant, award or other acquisition. The exercise price is $7.99, but no cash market purchase or sale of Xilio common stock is reported in this particular transaction.